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Abstract
Background: Psoriasis is a chronic inflammatory skin disease that can be successfully treated with
a mixture of fumaric acid esters (FAE) formulated as enteric-coated tablets for oral use. These
tablets consist of dimethylfumarate (DMF) and salts of monoethylfumarate (MEF) and its main
bioactive metabolite is monomethylfumarate (MMF). Little is known about the pharmacokinetics of
these FAE. The aim of the present study was to investigate the hydrolysis of DMF to MMF and the
stability of MMF, DMF and MEF at in vitro conditions representing different body compartments.
Results: DMF is hydrolyzed to MMF in an alkaline environment (pH 8), but not in an acidic
environment (pH 1). In these conditions MMF and MEF remained intact during the period of analysis
(6 h). Interestingly, DMF was hardly hydrolyzed to MMF in a buffer of pH 7.4, but was rapidly
hydrolyzed in human serum having the same pH. Moreover, in whole blood the half-life of DMF
was dramatically reduced as compared to serum. The concentrations of MMF and MEF in serum
and whole blood decreased with increasing time. These data indicate that the majority of the FAE
in the circulation are metabolized by one or more types of blood cells. Additional experiments with
purified blood cell fractions resuspended in phosphate buffered saline (pH 7.4) revealed that at
concentrations present in whole blood monocytes/lymphocytes, but not granulocytes and
erythrocytes, effectively hydrolyzed DMF to MMF. Furthermore, in agreement with the data
obtained with the pure components of the tablet, the enteric-coated tablet remained intact at pH
1, but rapidly dissolved at pH 8.
Conclusion: Together, these in vitro data indicate that hydrolysis of DMF to MMF rapidly occurs
at pH 8, resembling that within the small intestines, but not at pH 1 resembling the pH in the
stomach. At both pHs MMF and MEF remained intact. These data explain the observation that after
oral FAE intake MMF and MEF, but not DMF, can be readily detected in the circulation of human
healthy volunteers and psoriasis patients.
Background
Psoriasis is a chronic inflammatory skin disease character-
ized by epidermal hyperplasia and infiltration of inflam-
matory cells into skin lesions. Anti-psoriatic therapies are
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these anti-psoriatic therapies is often hampered by serious
adverse effects [1-5]. In this connection it is of interest that
already in 1959, Schweckendiek introduced fumaric acid,
an intermediate of the citric acid cycle, for the treatment
of his psoriasis [6]. The main adverse effect of fumaric acid
therapy, i.e. induction of gastric ulcers, was overcome by
application of a mixture of fumaric acid esters (FAE) with
great bioavailability [7]. This mixture, consisting of
dimethylfumarate (DMF) and salts of monoethylfuma-
rate (MEF), was formulated as enteric-coated tablets. This
systemic therapy, successfully applied by several German
[8,9] and Dutch [10,11] dermatologists, can be taken by
patients for a long period due to the excellent safety pro-
file [12]. Adverse effects that do occur are mostly mild and
transient and include facial flushing and gastro-intestinal
complaints. Pharmacokinetic data of FAE therapy are very
limited and mainly based on personal communications
[8,13]. For such a pharmacokinetic study, we first devel-
oped a highly sensitive method to determine concentra-
tions of FAE in human blood (Litjens et al., manuscript
submitted). In the present study, we investigated the
hydrolysis of DMF to its most bioactive metabolite mon-
omethylfumarate (MMF) and the stability of MMF, DMF
and MEF in different environments representing various
body compartments using this methodology.
Results
Stability of FAE and hydrolysis of DMF to MMF in buffers 
of various pH
DMF, MMF and MEF remained completely intact in a
buffer of pH 1 mimicking the pH in the stomach (Figure
1A and 1F). However, at pH 8 resembling the pH in the
small intestines DMF, the most abundant component of
the FAE tablet, was hydrolyzed to MMF (the half-life of
DMF amounted to 1.5 hr) (Figure 1B). Addition of MEF,
the other component of the FAE tablet, did not affect the
half-life of DMF (1.7 hr) (Figure 1G). MMF remained
intact (Figure 1B) in this buffer during the period of anal-
ysis (6 hr) as did MEF (Figure 1G).
To further examine the pH-dependency of the hydrolysis
of DMF to MMF, we measured concentrations of DMF and
MMF in phosphate buffers (with pH ranging from 6.5–8)
supplemented with DMF or the combination of DMF and
MEF. The results revealed that the half-life of DMF dra-
matically decreased with increasing pH values and the
maximal hydrolysis of DMF to MMF was seen at pH 8
(half life of DMF was 1.5 hr). For example, at pH 7.4 the
half-life of DMF amounted to 12.7 ± 1.0 hr (n = 3) (Figure
1C). In agreement with these results we observed that the
Fumaraat 120 tablet disintegrated completely between 1.5
and 2.5 hr in the alkaline, but not in the acidic, environ-
ment. The half-life of DMF in the tablet amounted to
approximately 2.3 hr (data not shown).
Changes in the concentrations of DMF, MMF and MEF in 
serum and whole blood
Since FAE must enter the circulation to exert their anti-
psoriatic effects at the affected skin site [14], we deter-
mined the hydrolysis of DMF to MMF and examined the
stability of MMF, DMF and MEF in both normal human
serum and whole blood (both with a pH of 7.4). The half-
life of DMF in serum (Table 1 and Figure 1D) is dramati-
cally shorter (p < 0.05) than that in a buffer of the same
pH. MMF (Figure 1D and 1I) and MEF (Figure 1I) concen-
trations slowly decreased in serum during the period of
analysis (6 hr). Furthermore, the half-life of DMF was
even shorter (p < 0.05) in whole blood than in serum
(Table 1 and Figure 1E), indicating that circulating cells
are also involved in the hydrolysis of DMF to MMF. Fur-
thermore, concentrations of MMF (Figure 1E and 1J) and
MEF (Figure 1J) in whole blood decreased steadily during
the period of analysis (6 hr), indicating that they may be
metabolized by blood cells as well.
To find out which blood cell type(s) is (are) responsible
for the hydrolysis of FAE in whole blood, hydrolysis of
DMF in a buffer of pH 7.4 by purified blood cell fractions
was analyzed. The results revealed that monocytes/lym-
phocytes (Figure 2A), but not granulocytes (Figure 2B)
and erythrocytes (Figure 2C), at concentrations present in
whole blood effectively hydrolyzed DMF to MMF.
Discussion
A major finding of the present study is that hardly any
DMF was hydrolyzed in a buffer of pH ≤ 7.4, whereas at
pH 8, resembling the pH of the small intestines, this FAE
was effectively hydrolyzed to its active metabolite MMF. It
should be noted that MMF (and MEF) remained stable in
these buffers. We realize that using acidic or alkaline buff-
ers to mimick the conditions in body compartments, like
the stomach and the small intestines, is only a first
attempt to investigate the in vitro pharmacokinetics of
FAE. For example, no enzymes, e.g. esterases, are present
in these buffers whereas they are in these body compart-
ments. In this connection, Werdenberg and collegues [15]
recently showed that in the small intestines, the concen-
trations of MEF and MMF remained unaffected, whereas
concentrations of DMF decreased by the action of este-
rases, such as carboxyl- and choline-esterases in this com-
partment. Esterase activity is also present in the liver
which can cause a rapid disappearance of the various FAE
from the circulation. Absorption of FAE from the small
intestines into the circulation is not only dependent on
the permeability of the intestinal membrane for the vari-
ous FAE (permeability increases with increased acyl-chain
length and increased lipophilicity), but also on the stabil-
ities of the various FAE in the small intestines and liver.
Clearly, hydrolysis of DMF to MMF is not only dependentPage 2 of 7
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Changes in the concentrations of the various FAE in different environments. DMF at a concentration of 2 mg/L or 
the combination of 2 mg/L DMF and 1.4 mg/L MEF were placed at 37°C in 0.1 N HCl; pH 1 (A, F), 0.1 M sodium phosphate 
buffer; pH 8 (B, G), 0.1 M sodium phosphate buffer; pH 7.4 (C, H), normal human serum (D, I) or whole blood (E, J). At various 
intervals thereafter samples were collected and the MMF (squares), DMF (circles) and MEF (triangles) concentrations were 
measured using HPLC. Results are a representative experiment of at least 3 independent experiments.
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esterases.
Another important finding of this study is that the half-
life of DMF in whole blood is considerably shorter than
that in serum, although the pH of both blood and serum
is 7.4. To explain this difference in hydrolysis of DMF in
whole blood and serum we considered the possibility that
blood cells also hydrolyze DMF to MMF. Using purified
blood cell fractions resuspended in PBS (pH 7.4) we
found that monocytes/lymphocytes, but not granulocytes
and erythrocytes, at concentrations present in whole
blood effectively hydrolyzed DMF to MMF. The rapid
removal of DMF from PBS after addition of granulocytes
and erythrocytes suggests that these blood cells bind DMF.
It should be realized that MMF (and MEF) most likely
enter the circulation of psoriasis patients in order to exert
their antipsoriatic effects in the skin lesions. In agreement
we detected MMF and MEF, but not DMF, in the circula-
tion of healthy volunteers and psoriasis patients after oral
intake of Fumaraat 120® tablets [[16], Litjens et al., manu-
script submitted; Litjens et al., unpublished data]. Our
observation that the MMF is more rapidly removed from
whole blood than from serum could indicate that MMF
(and MEF) is taken up by blood cells and perhaps further
metabolized into FA, which subsequently fuels the citric
acid cycle, as suggested earlier by Joshi (personal commu-
nication). The different interactions between FAE and
blood cells may affect their functional activities, as has
been reported earlier [14,17-19], thus contributing to the
beneficial effects of FAE therapy.
Conclusions
Together, these in vitro data indicate that DMF is almost
completely hydrolyzed to MMF at an alkaline pH, but not
at an acidic pH, suggesting that this hydrolysis occurs
mainly within the small intestines and not in the stom-
ach. Most likely, MMF and MEF are then absorbed in the
circulation where they interact with blood cells and per-
haps cells in the psoriatic lesions. The different interac-
tions between these FAE and the various cell types may
explain the beneficial effects of FAE in psoriasis. Finally,
these in vitro experimental data will be key to the pharma-
cokinetic analysis of oral FAE in human healthy volun-
teers and psoriasis patients.
Methods
Fumaric acid esters (FAE)
The following FAE were used: dimethylfumarate (DMF;
purity > 97%, TioFarma, Oud-Beijerland, The Nether-
lands), calcium-monoethylfumarate (MEF; purity > 97%,
Tiofarma), monomethylfumarate (MMF; purity > 97%,
AstraZeneca R&D, Charnwood, Loughborough, UK). In
addition, the enteric-coated, magisterial manufactured
tablet (named Fumaraat 120®; TioFarma), containing 120
mg of DMF and 95 mg of calcium-MEF was investigated
in this study.
Table 1: Hydrolysis rate of DMF to MMF and half-lives of DMF in different environments. To analyze under which circumstances DMF 
can be hydrolyzed to MMF and whether MEF affects the hydrolysis of DMF into MMF, we determined the hydrolysis rates for DMF in 
different environments. In short, a 0.1 M sodium phosphate buffer, human serum and whole blood (all pH 7.4) were spiked with either 
2 mg/L of DMF or with the combination of 2 mg/L of DMF and 1.4 mg/L of MEF and at several intervals thereafter, samples were taken 
and prepared in order to measure the concentration of DMF, MMF and MEF by HPLC. Subsequently, after calculating the area under 
the curves for DMF (AUC_DMF) and MMF (AUC_MMF), the following model [16] was used to fit the concentrations of MMF and to 
estimate the kDMF (rate of hydrolysis of DMF into MMF) in these solutions: [MMF]t = i = (kDMF*AUC_DMF)-(kMMF*AUC_MMF) + [MMF]t 
= 0. In addition, the half-life was calculated using the following formula: t1/2 = ln(2)/k. Data are means and SD (n = 3). # and * significant 
(p < 0.05) different value between buffer and and serum and serum and whole blood, respectively.
kdmf (h-1) t1/2 (h)
Buffer
Spiked with:
DMF 0.06 (0.004) 12.72 (1.04)
DMF+MEF 0.05 (0.01) 15.17 (1.88)
Serum
Spiked with:
DMF 1.96 (0.47) 0.37 (0.08) #
DMF+MEF 2.20 (0.25) 0.32 (0.05) #
Whole blood
Spiked with:
DMF 8.01 (3.78) 0.10 (0.04)*
DMF+MEF 10.08 (2.74) 0.07 (0.02)*Page 4 of 7
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Hydrolysis of DMF to MMF by various types of blood cells. Monocytes/lymphocytes, granulocytes, and erythrocytes 
were purified from blood of healthy volunteers using centrifugational techniques. Next, the various cell types were resus-
pended in PBS pH 7.4 to concentrations present in whole blood, e.g. 1 × 106/mL monocytes/lymphocytes (A), 5 × 106/mL gran-
ulocytes (B) and 5 × 109/mL erythrocytes (C), and then DMF was added to a final concentration of 2 mg/L. At various intervals 
thereafter samples were collected and the MMF (squares) and DMF (circles) concentrations were measured using HPLC. 
Results are a representative experiment of 3–4 independent experiments.
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To investigate the stability of DMF, MMF and MEF and the
hydrolysis of DMF to MMF in several environments repre-
senting various aspects of different body compartments,
0.1 N HCl with pH 1 and 0.1 M sodium phosphate buffer
with pH 8 were spiked with 2 mg/L of DMF, MMF, MEF or
the combination of 2 mg/L of DMF and 1.4 mg/L MEF, to
resemble the ratio of these two components in the
Fumaraat 120® tablet. In addition, to determine the
release of the contents of a Fumaraat 120® tablet and the
hydrolysis of DMF to MMF at pH 1 (0.1 N of HCl) and pH
8 (0.1 M of sodium phosphate buffer), the tablet was
placed in these buffers and at various intervals samples
were taken and prepared for measurement of the concen-
trations of DMF, MMF and MEF by high-performance liq-
uid chromatography (HPLC) as described below.
To further investigate the effect of the pH on the hydroly-
sis of DMF to MMF, 0.1 M sodium phosphate buffers with
pH values ranging from 6.5–8 were spiked with DMF and
the combination of DMF and MEF. At several intervals
thereafter, samples were taken, and then prepared for
measurement of the various FAE by HPLC.
As the current buffers lack proteins, no extraction proce-
dure was necessary and the concentrations of the various
FAE in the samples could be directly quantified by HPLC
(see below).
Concentrations of DMF, MMF and MEF in serum and 
whole blood
As described above, serum and whole blood from 3 vol-
unteers was spiked with 2 mg/L of DMF, MMF, MEF or the
combination of 2 mg/L of DMF and 1.4 mg/L MEF. All
volunteers were healthy as assessed by a full medical
screening.
At several intervals, samples were taken, and then pre-
pared for measurement of the various FAE by HPLC. In
short, serum and whole blood contained proteins known
to interfere with the measurement of FAE. To overcome
this problem, the various FAE were extracted from serum
and whole blood samples and subsequently the concen-
trations were measured by HPLC (see below).
Effects of purified blood cell fractions on the hydrolysis of 
DMF in PBS (pH 7.4)
The various blood cell fractions were obtained from blood
of healthy volunteers using centrifugational techniques as
described earlier [17,19]. In short, blood was subjected to
Ficoll Amidotrizoate (ρ = 1.077 gm/L; Dept. of Pharmacy,
Leiden University Medical Center, Leiden, The Nether-
lands) density gradient centrifugation (440 g 20 min at
18°C). After resuspension of the cells in the pellet in
phosphate buffered saline (PBS; pH 7,4) the granulocytes
were purified by plasmasteril (Fresenius AG, Bad Hom-
burg, Germany) sedimentation (1 g) for 10 min at 37°C,
washed with PBS and the contaminating erythrocytes
were lysed with distilled water. Erythrocytes were
obtained after washing the cells in the Ficoll-Amidotri-
zoate pellet three times with PBS supplemented with 0.1
IU heparin. Cells in the Ficoll-Amidotrizoate interphase
(monocytes/lymphocytes) were washed three times with
PBS containing 0.5 IU heparin and then resuspended in
PBS pH 7.4. Next, suspensions of 1 × 106 monocytes and
lymphocytes/mL PBS, 4 × 106 granulocytes/mL PBS, and 5
× 109 erythrocytes/mL PBS were spiked with 2 mg/L DMF.
Again, at several intervals samples were taken and concen-
trations of the various FAE were measured as described
below.
Sample preparation and HPLC analysis
The concentrations of the various fumarates in serum
samples were determined as described (Litjens et al., sub-
mitted for publication). Briefly, after precipitation of
serum proteins with acetonitrile, DMF in the samples was
quantitated by HPLC. The sample preparation for MMF
and MEF required a protein precipitation step with meta-
phosphoric acid followed by extraction with diethylether
and additional pH-lowering to pH 0.5. Next, sodium
chloride was added before centrifugation at 12,000 g.
Thereafter, the ether layer was transferred to a glass vial
and after evaporation the residue reconstituted in metha-
nol: 0.1 M potassium phosphate buffer (KH2PO4/
K2HPO4; pH 7.5) supplemented with 5 mM tetrabutylam-
monium dihydrogen phosphate 1:1 (v/v).
Concentrations of DMF, MMF, and MEF were determined
on a HPLC apparatus (Spectra SERIES P100, Thermo
Separation Products, Breda, The Netherlands) equipped
with an Alltima C18 (5 µ 250*4.6; Alltech, Lokeren, Bel-
gium) column and an Alltima Guard C18 precolumn (5 µ
7.5*4.6; Alltech, Lokeren, Belgium) using methanol:water
30:70 (v/v) as an eluent for DMF and methanol: potas-
sium phosphate buffer supplemented with 5 mM
tetrabutylammonium dihydrogen phosphate 20:80 (v/v)
as eluent for MMF and MEF. The limit of detection for all
three compounds amounted to 0.01 mg/L, the coefficient
of variation for MMF, DMF and MEF was 7%, 8% and 9%
at 0.5 mg/L, respectively (n = 4), and the recovery of MMF,
DMF and MEF amounted to 75 ± 7%, 98 ± 3%, 67 ± 7%
(n = 6). Standard curves constructed with purified FAE in
buffers or human serum were used to quantify the con-
centrations of FAE in the various samples of these buffers
and human serum or whole blood, respectively.
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